由于USPTO专利争端积压,林业发展局对生物相似的药物审批的推动可能会延迟。 FDA's biosimilar drug approval push may delay due to USPTO patent dispute backlog.

林业发展局加快批准生物类药物的举措旨在降低成本和增加获取机会,由于美国专利和商标局面临的挑战,可能面临延误,该办公室负责监督非专利药品制造商和品牌药品制造商之间的专利纠纷。 The FDA’s initiative to accelerate the approval of biosimilar drugs, aimed at lowering costs and increasing access, may face delays due to challenges at the U.S. Patent and Trademark Office, which oversees patent disputes between generic and brand-name drug manufacturers.